Genome & Company (KOSDAQ:314130)
South Korea
· Delayed Price · Currency is KRW 6,350.00
-160.00 (-2.46%)
At close: Apr 28, 2026
Genome & Company Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Net Income | -6,428 | -20,112 | -47,466 | -51,838 | -34,117 | Upgrade
|
| Depreciation & Amortization | 6,672 | 7,447 | 8,272 | 9,462 | 2,591 | Upgrade
|
| Loss (Gain) From Sale of Assets | 76.89 | 79.51 | 77.11 | -0.69 | 12.93 | Upgrade
|
| Asset Writedown & Restructuring Costs | 3,095 | 8,367 | 2,325 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 583.4 | -40.28 | -46.44 | - | - | Upgrade
|
| Stock-Based Compensation | 3,155 | 2,342 | 12,066 | 6,083 | 5,566 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | - | -12.92 | - | Upgrade
|
| Other Operating Activities | -23,431 | -8,964 | -4,648 | -3,864 | -1,658 | Upgrade
|
| Change in Accounts Receivable | 153.34 | -459.04 | 1,126 | -1,145 | 11.95 | Upgrade
|
| Change in Inventory | -308.83 | -1,898 | -1,694 | -886.4 | -154.36 | Upgrade
|
| Change in Accounts Payable | 40.29 | 88.24 | 132.77 | -139.79 | 14.8 | Upgrade
|
| Change in Other Net Operating Assets | -1,995 | -3,182 | -2,368 | -1,209 | 1,573 | Upgrade
|
| Operating Cash Flow | -18,387 | -16,331 | -32,224 | -43,550 | -26,159 | Upgrade
|
| Capital Expenditures | -284.66 | -3,970 | -18,853 | -6,849 | -2,875 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.96 | 0.5 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -26,721 | Upgrade
|
| Sale (Purchase) of Intangibles | -151.18 | -216.34 | -189.09 | -427.29 | -504.78 | Upgrade
|
| Investment in Securities | -7,528 | 15,849 | 4,742 | 7,453 | -29,609 | Upgrade
|
| Other Investing Activities | 470.62 | -112.66 | -1,129 | -99.49 | -100.48 | Upgrade
|
| Investing Cash Flow | -7,494 | 11,551 | -15,430 | 77.52 | -59,810 | Upgrade
|
| Long-Term Debt Issued | 142.22 | 5,830 | 32,509 | - | - | Upgrade
|
| Long-Term Debt Repaid | -20,908 | -568.03 | -2,023 | -1,645 | -820.29 | Upgrade
|
| Net Debt Issued (Repaid) | -20,766 | 5,262 | 30,487 | -1,645 | -820.29 | Upgrade
|
| Issuance of Common Stock | - | 33.84 | 81.49 | 126.83 | 1,248 | Upgrade
|
| Repurchase of Common Stock | -54,155 | - | - | - | - | Upgrade
|
| Other Financing Activities | 27,023 | -49.78 | - | 35.61 | 57.69 | Upgrade
|
| Financing Cash Flow | -22,173 | 5,246 | 30,568 | 78,550 | 17,617 | Upgrade
|
| Foreign Exchange Rate Adjustments | -1,897 | 8,727 | 1,226 | 1,089 | 453.3 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | 0 | -0 | 0 | -0 | Upgrade
|
| Net Cash Flow | -49,950 | 9,192 | -15,860 | 36,167 | -67,898 | Upgrade
|
| Free Cash Flow | -18,671 | -20,301 | -51,077 | -50,399 | -29,034 | Upgrade
|
| Free Cash Flow Margin | -75.94% | -73.17% | -357.28% | -357.83% | -6434.20% | Upgrade
|
| Free Cash Flow Per Share | -595.46 | -666.18 | -1808.70 | -1790.39 | -1080.03 | Upgrade
|
| Cash Interest Paid | 596.87 | 587.12 | 310.78 | 170.8 | 52.71 | Upgrade
|
| Cash Income Tax Paid | 41.21 | 70.95 | 92.92 | 54.31 | 10.84 | Upgrade
|
| Levered Free Cash Flow | -21,481 | -17,433 | -31,442 | -35,323 | -17,129 | Upgrade
|
| Unlevered Free Cash Flow | -18,531 | -15,220 | -30,355 | -35,213 | -17,095 | Upgrade
|
| Change in Working Capital | -2,110 | -5,451 | -2,804 | -3,379 | 1,446 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.